Dimerix Expands Kidney Disease Pipeline with DMX-652 Phase 2 Acquisition and Secures Non-Dilutive Funding

Strategic Acquisition of DMX-652 Broadens Dimerix’s Pipeline into Acute Kidney Injury Therapeutics

Dimerix has acquired DMX-652, a selective inhibitor of USP30, a mitochondrial enzyme that impedes the clearance of damaged mitochondria. This acquisition significantly broadens the company’s clinical pipeline beyond its lead asset DMX-200 and positions Dimerix to address acute kidney injury (AKI), a common and severe condition with high unmet medical needs. The asset includes composition of matter patent protection, an active US Investigational New Drug (IND) application with FDA-approved Phase 2 clinical trial protocol, and sufficient pharmaceutical-grade drug product plus manufacturing methodology for the Phase 2 study.

DMX-652 is administered orally once daily to support mitochondrial quality control in damaged kidney cells. Its mechanism targets pathways involved in AKI progression caused by ischemia, toxins, sepsis, and other renal and non-renal conditions. This acquisition grants Dimerix immediate access to an advanced clinical program with regulatory clearance to proceed, reducing development risk and enabling rapid initiation of human trials. The Phase 2 trial aims to assess DMX-652’s ability to prevent kidney injury and preserve renal function in affected patients.

Acute Kidney Injury Represents a Large Clinical Opportunity with No Approved Disease-Modifying Treatments

Acute kidney injury is characterised by a rapid decline in kidney function within hours, often leading to significant morbidity and mortality. In the US, the addressable patient population is estimated between 100,000 and 133,000 annually, making AKI a potential orphan indication. AKI frequently occurs in high-risk clinical settings such as cardiac surgery and sepsis, posing a substantial clinical burden with no approved therapies targeting the underlying disease mechanisms.

Currently, treatment for AKI is limited to supportive care, with no disease-modifying options available. AKI is associated with rapid kidney function deterioration, increased risk of chronic kidney disease progression, and long-term complications that may necessitate dialysis or transplantation. Patients with AKI face elevated risks of poor outcomes and extended hospital stays. By developing DMX-652, Dimerix targets a significant unmet need with a well-defined patient population, positioning itself to serve numerous hospitalized patients across diverse clinical scenarios.

DMX-200 Advances in Phase 3 ACTION3 Trial for FSGS with Orphan Drug Status

Dimerix’s lead candidate, DMX-200, is in Phase 3 clinical development for focal segmental glomerulosclerosis (FSGS), a rare, life-threatening kidney disease characterised by progressive scarring of the glomeruli, leading to proteinuria, kidney function loss, and often end-stage renal disease. FSGS has an inflammatory component involving monocyte and macrophage activation. In the US, over 40,000 individuals live with FSGS, including adults and children, yet no therapies are specifically approved for this condition.

The upcoming investor webinar will provide updates on the Phase 3 ACTION3 clinical trial of DMX-200. This chemokine receptor (CCR2) antagonist is administered alongside standard-of-care angiotensin II type I receptor blockers (AT1R blockers). DMX-200 is protected by granted patents in multiple jurisdictions until 2032, with global patent applications potentially extending protection to 2042. It holds Orphan Drug Designation in the US, Europe, UK, and Japan, offering regulatory incentives and market exclusivity. For patients with progressive or treatment-resistant FSGS, progression to end-stage kidney disease can occur within five years, highlighting the urgent need for effective therapies.

Non-Dilutive Loan Facility Bolsters Dimerix’s Financial Position Without Equity Dilution

Alongside the DMX-652 acquisition, Dimerix secured a non-dilutive loan facility, enabling capital raising without diluting existing shareholders. Such funding mechanisms are vital for clinical-stage biopharmaceutical companies managing multiple programs, as they provide financial resources while preserving ownership stakes.

CEO Dr Nina Webster will discuss the company’s funding status during the investor webinar on Friday, 17 July 2026 at 10:30am AEST. The combination of the loan facility and DMX-652 acquisition indicates a structured capital approach supporting both the Phase 3 ACTION3 trial and initiation of the Phase 2 DMX-652 study. Investors will likely monitor loan terms, repayment schedules, and milestones, which impact cash runway and future financing needs.

Five Commercial Partners Enhance Dimerix’s Global Development and Market Reach

Dimerix has built a network of five commercial partners supporting global development and future market access for its kidney disease therapies. This partnership model is common among clinical-stage biopharmaceutical firms, providing access to development expertise, regulatory pathways, manufacturing scale-up, and commercial distribution. The diverse partner base reflects confidence in Dimerix’s pipeline and validates the unmet medical needs addressed.

These collaborations aim to maximize patient access worldwide while creating shareholder value. They may also offer non-dilutive or partially dilutive funding, milestone payments, or royalties, reducing reliance on equity capital. The geographic and therapeutic diversity of partners underscores Dimerix’s specialization in kidney diseases with commercial appeal.

Investor Webinar Offers Live Update on Clinical Progress and Strategic Plans

Dimerix invites shareholders, investors, and brokers to a live investor webinar on Friday, 17 July 2026 at 10:30am AEST. CEO Dr Nina Webster will cover the DMX-652 acquisition, non-dilutive loan facility, funding position, and Phase 3 ACTION3 trial progress for DMX-200 in FSGS. Attendees can submit questions during registration or live, enabling direct interaction with company leadership.

The webinar demonstrates Dimerix’s commitment to transparent communication on material developments. Presentation materials accompany the update, and registration via Zoom ensures broad accessibility. This session provides investors insight into the rationale behind the DMX-652 acquisition, funding structure, and strategic pipeline positioning.

Robust Patent Portfolio and Regulatory Designations Support Long-Term Market Exclusivity

Dimerix holds granted patents for DMX-200 across multiple territories through 2032, with global applications potentially extending protection to 2042. This patent coverage supports market exclusivity, critical for rare disease treatments with smaller patient populations but higher pricing due to unmet needs. DMX-200 also has Orphan Drug Designation in the US, Europe, UK, and Japan, offering regulatory incentives such as market exclusivity, tax credits, and reduced fees.

The DMX-652 acquisition includes composition of matter patent protection, establishing intellectual property rights in acute kidney injury. Given the estimated US patient population of 100,000 to 133,000 annually, orphan designation for DMX-652 is a potential regulatory pathway. The combination of patent protection, orphan drug status, and FDA-approved Phase 2 protocol creates a favorable environment for development and commercialization, mitigating generic competition risks and providing development incentives.

Clinical Trial Milestones and Regulatory Approvals Set Stage for Upcoming Value Catalysts

The update highlights the Phase 3 ACTION3 trial for DMX-200 in FSGS, with CEO Dr Webster providing progress details during the webinar. Phase 3 trials are pivotal, multi-site studies confirming efficacy and safety, representing a major de-risking step toward regulatory approval.

For DMX-652, the FDA-approved Phase 2 clinical trial protocol enables rapid trial commencement without regulatory delays. The asset includes pharmaceutical-grade drug product and manufacturing know-how to facilitate study initiation. Investors will watch for enrollment progress, interim safety, and efficacy data that could validate the mitochondrial quality control mechanism and support advancement to Phase 3. Together, the Phase 3 FSGS and Phase 2 AKI programs offer multiple clinical milestones in the coming years.

Kidney Disease Market Potential and Dimerix’s Leadership in Rare Nephrology Therapeutics

Dimerix operates in the kidney disease therapeutics market, marked by high unmet needs, limited approved treatments, and significant patient morbidity and mortality. Both FSGS and AKI are serious conditions lacking disease-modifying therapies. FSGS affects over 40,000 people in the US, with no approved treatments and a disease course that can lead to end-stage renal disease within five years for resistant cases. Disease recurrence post-transplant occurs in up to 60% of patients, underscoring the need for systemic treatments.

Dimerix’s exclusive focus on kidney diseases differentiates it from larger pharma companies with diversified portfolios. Its dual-program strategy addressing chronic progressive kidney disease (FSGS) and acute kidney injury reduces reliance on a single asset. Supported by five commercial partners, orphan drug designations, and patent protections, Dimerix is positioned to establish a sustainable commercial presence in rare nephrology. The kidney disease market opportunity is substantial, given the prevalence of FSGS, the sizeable AKI patient population, and the lack of effective therapies available to patients and clinicians.